Technical Analysis for GHRS - GH Research PLC
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 10.95 | 13.94% | 1.34 |
GHRS closed up 13.94 percent on Wednesday, November 20, 2024, on 1.49 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 200 DMA | Bullish | 0.00% | |
Expansion Breakout | Bullish Swing Setup | 0.00% | |
Stochastic Reached Overbought | Strength | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Multiple of Ten Bullish | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Up 4 Days in a Row | Strength | 0.00% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 21 hours ago |
Up 1% | about 21 hours ago |
Upper Bollinger Band Resistance | about 21 hours ago |
60 Minute Opening Range Breakdown | 1 day ago |
Possible NR7 | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/15/2024
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Psychoactive Drugs Entheogens Treatment Resistant Depression Psychiatric And Neurological Disorders N Dimethyltryptamine
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Psychoactive Drugs Entheogens Treatment Resistant Depression Psychiatric And Neurological Disorders N Dimethyltryptamine
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 14.99 |
52 Week Low | 5.05 |
Average Volume | 63,557 |
200-Day Moving Average | 10.15 |
50-Day Moving Average | 7.87 |
20-Day Moving Average | 8.67 |
10-Day Moving Average | 9.28 |
Average True Range | 0.80 |
RSI (14) | 78.72 |
ADX | 28.03 |
+DI | 32.91 |
-DI | 10.14 |
Chandelier Exit (Long, 3 ATRs) | 8.69 |
Chandelier Exit (Short, 3 ATRs) | 9.42 |
Upper Bollinger Bands | 10.24 |
Lower Bollinger Band | 7.11 |
Percent B (%b) | 1.23 |
BandWidth | 36.10 |
MACD Line | 0.55 |
MACD Signal Line | 0.36 |
MACD Histogram | 0.1911 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.34 | ||||
Resistance 3 (R3) | 13.12 | 12.10 | 12.94 | ||
Resistance 2 (R2) | 12.10 | 11.50 | 12.21 | 12.80 | |
Resistance 1 (R1) | 11.53 | 11.12 | 11.82 | 11.75 | 12.67 |
Pivot Point | 10.51 | 10.51 | 10.66 | 10.62 | 10.51 |
Support 1 (S1) | 9.94 | 9.91 | 10.23 | 10.16 | 9.23 |
Support 2 (S2) | 8.92 | 9.53 | 9.03 | 9.10 | |
Support 3 (S3) | 8.35 | 8.92 | 8.96 | ||
Support 4 (S4) | 8.57 |